Claims for Patent: 9,321,807

Summary for Patent: 9,321,807

Title:	Crystal forms
Abstract:	The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in any one of FIGS. 1-4.
Inventor(s):	Chen; Shuang (Gurnee, IL), Gates; Bradley D. (Mt. Prospect, IL), Sheikh; Ahmad Y. (Deerfield, IL)
Assignee:	AbbVie Inc. (North Chicago, IL)
Application Number:	14/731,765
Patent Claims:	1. A crystalline form of Compound I, ##STR00002## wherein said crystalline form has characteristic peaks in its PXRD pattern at values of two theta as described in any one of Tables 1a, 2a, 3a, and 4a. 2. A crystalline form of Compound I, ##STR00003## wherein said crystalline form has characteristic peaks in its PXRD pattern as described in any one of FIGS. 1-4. 3. A crystalline form of Compound I, ##STR00004## wherein said crystalline form has characteristic peaks in its PXRD pattern at values of two theta (.degree.2.theta.) of 8.4, 8.9, 11.1, 12.2, 14.5, 15, 15.9, 17.4, 17.8, and 22.2. 4. The crystalline form of claim 3, wherein said crystalline form has characteristic peaks in its PXRD pattern at values of two theta (.degree.2.theta.) of 8.4, 8.9, 10.2, 11.1, 12.2, 12.5, 13.2, 13.7, 14.5, 15, 15.5, 15.9, 17.4, 17.8, 19.6, 19.9, 21.1, 22.2, 22.7, and 23.9. 5. The crystalline form of claim 4, wherein said crystalline form has characteristic peaks in its PXRD pattern at values of two theta (.degree.2.theta.) of 6.7, 8.4, 8.9, 9.9, 10.2, 11.1, 12.2, 12.5, 13.2, 13.7, 14.5, 15, 15.5, 15.9, 17.4, 17.8, 18.1, 18.9, 19, 19.6, 19.9, 21.1, 21.8, 22.2, 22.7, 22.8, 23.2, 23.9, 24.6, and 25.1. 6. A composition, comprising a crystalline form according to claim 1. 7. A process for making a pharmaceutical composition comprising Compound I, comprising dissolving a crystalline form according to claim 1. 8. A composition, comprising a crystalline form according to claim 2. 9. A composition, comprising a crystalline form according to claim 3. 10. A composition, comprising a crystalline form according to claim 4. 11. A composition, comprising a crystalline form according to claim 5. 12. A process for making a pharmaceutical composition comprising Compound I, comprising dissolving a crystalline form according to claim 2. 13. A process for making a pharmaceutical composition comprising Compound I, comprising dissolving a crystalline form according to claim 3. 14. A process for making a pharmaceutical composition comprising Compound I, comprising dissolving a crystalline form according to claim 4. 15. A process for making a pharmaceutical composition comprising Compound I, comprising dissolving a crystalline form according to claim 5. 16. The crystalline form of claim 1, wherein said crystalline form has characteristic peaks in its PXRD pattern at values of two theta as described in Table 2a. 17. The crystalline form of claim 1, wherein said crystalline form has characteristic peaks in its PXRD pattern at values of two theta as described in Table 3a. 18. The crystalline form of claim 1, wherein said crystalline form has characteristic peaks in its PXRD pattern at values of two theta as described in Table 4a. 19. The crystalline form of claim 2, wherein said crystalline form has characteristic peaks in its PXRD pattern as described in FIG. 1. 20. The crystalline form of claim 2, wherein said crystalline form has characteristic peaks in its PXRD pattern as described in FIG. 2. 21. The crystalline form of claim 2, wherein said crystalline form has characteristic peaks in its PXRD pattern as described in FIG. 3. 22. The crystalline form of claim 2, wherein said crystalline form has characteristic peaks in its PXRD pattern as described in FIG. 4.